Skip to main content
Journal cover image

Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab).

Publication ,  Journal Article
Kong, HH; Prose, NS; Ware, RE; Hall, RP
Published in: Pediatr Dermatol
2005

Pemphigus vulgaris is an uncommon autoimmune blistering skin disorder that is particularly rare in children. Immunosuppressive treatment can be challenging. Rituximab (anti-CD20 monoclonal antibody) has been used to treat autoimmune disorders by depletion of CD20 B cells. Successful rituximab therapy has been reported in adults with refractory pemphigus vulgaris. We present a girl with childhood pemphigus vulgaris unresponsive to treatment with azathioprine, mycophenolate mofetil, plasmapheresis, and intravenous immunoglobulin with systemic prednisone who responded to treatment with rituximab. She had a corresponding decline in circulating antibodies against desmoglein 1 and 3 and a decline in diphtheria and tetanus-specific antibody titers.

Duke Scholars

Published In

Pediatr Dermatol

DOI

ISSN

0736-8046

Publication Date

2005

Volume

22

Issue

5

Start / End Page

461 / 464

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Treatment Failure
  • Rituximab
  • Pemphigus
  • Immunosuppressive Agents
  • Immunologic Factors
  • Humans
  • Female
  • Dermatology & Venereal Diseases
  • Antigens, CD20
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kong, H. H., Prose, N. S., Ware, R. E., & Hall, R. P. (2005). Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab). Pediatr Dermatol, 22(5), 461–464. https://doi.org/10.1111/j.1525-1470.2005.00118.x
Kong, Heidi H., Neil S. Prose, Russell E. Ware, and Russell P. Hall. “Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab).Pediatr Dermatol 22, no. 5 (2005): 461–64. https://doi.org/10.1111/j.1525-1470.2005.00118.x.
Kong HH, Prose NS, Ware RE, Hall RP. Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab). Pediatr Dermatol. 2005;22(5):461–4.
Kong, Heidi H., et al. “Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab).Pediatr Dermatol, vol. 22, no. 5, 2005, pp. 461–64. Pubmed, doi:10.1111/j.1525-1470.2005.00118.x.
Kong HH, Prose NS, Ware RE, Hall RP. Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab). Pediatr Dermatol. 2005;22(5):461–464.
Journal cover image

Published In

Pediatr Dermatol

DOI

ISSN

0736-8046

Publication Date

2005

Volume

22

Issue

5

Start / End Page

461 / 464

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Treatment Failure
  • Rituximab
  • Pemphigus
  • Immunosuppressive Agents
  • Immunologic Factors
  • Humans
  • Female
  • Dermatology & Venereal Diseases
  • Antigens, CD20